Scinai Immunotherapeutics Ltd. secured approximately $4 million through a private placement and warrant inducement agreement with a life sciences investor. The funds will support the expansion of its contract development and manufacturing organization (CDMO) platform, advance customer programs, and invest in its immunotherapy pipeline. The transaction includes the sale of American Depositary Shares and Series A-1 warrants exercisable over five years. Closing is expected around October 15, 2026, with proceeds excluding future warrant exercises. This financing aims to bolster Scinai's growth strategy in biopharmaceutical services and immunology-focused therapeutics.
Scinai Immunotherapeutics' recent $4 million financing is presented here with relevant market data for context. As of Oct 14, 2026 19:01 WIB, 105 of 150 health-sector US stocks on Pluang rose while 40 fell. Notable movers include AstraZeneca plc at USD 158.67 with a 1.83% increase and 58% sell order activity, Novartis AG at USD 144.94 up 1.78%, and Sana Biotechnology Inc at USD 2.45 rising 1.66% with 92% buy order activity.
BlackRock reported a strong third quarter with adjusted earnings of $15.93 per share, beating estimates by a wide margin and marking a 38% increase year-over-year. Revenue grew 19% to $7.75 billion, driven by $205 billion in net client inflows, inclu...
Home BancShares will release its Q3 2026 earnings report on October 14, with analysts expecting earnings per share of $0.64 and revenue around $293-$294 million, marking a 5.5% revenue increase and 4.9% EPS growth from last year. The bank's P/E ratio...
Hyperion Materials & Technologies has acquired The Ultra-Met Company, a tungsten carbide manufacturer based in Urbana, Ohio, to expand its capabilities in serving the US aerospace and defense sectors. Ultra-Met works closely with the US Department of...
Morgan Stanley reported Q3 earnings per share of $3.03, surpassing analyst estimates of $2.93 and $2.83 consensus. Revenue reached $20.34 billion, a 12% increase year-over-year and above the $19.93 billion estimate. Strong equity trading and record w...
Bank of New York Mellon is set to report its Q3 2026 earnings, with analysts expecting earnings per share of $2.27 and revenue of $5.55 billion. This represents an 18.3% increase in earnings and a 9.5% rise in revenue compared to the previous year, d...
